Image: FG Trade, via Getty Images
Senate committee on health also seeks clarity over data used for research
Democrat leaders of committees in the House of Representatives have called on the federal medicines regulator to widen the diversity of populations used in clinical trials.
More inclusive clinical trials would increase patients’ confidence in new treatments, representatives including health subcommittee ranking member Anna Eshoo wrote to Food and Drug Administration commissioner Robert Califf.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.